When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IMGN - ImmunoGen not quite there with mirvetuximab soravtansine NDA; shares down 5% premarket
ImmunoGen Inc.
ImmunoGen (NASDAQ:IMGN) slips 5% premarket on light volume in reaction to its announcement that the FDA has recommended a new Phase 3 clinical trial evaluating antibody-drug conjugate mirvetuximab soravtansine in patients with high folate receptor alpha-positive, platinum-resistant ovarian cancer.